Novartis AG [NVS] is -11.81% lower this YTD. Is it still time to buy?


Novartis AG [NYSE: NVS] The stock went on a downward trajectory as it fell more than -0.52% on Thursday, which is a one-week price drop of less than -4.46%. Company report on September 22 2022 Novartis unveils focused new strategy, backed by eight potential brands with multibillion-dollar peak sales and deep pipelines, at the Meet the Management event.

Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now .

sponsored by

The transformation into a pure innovative pharmaceutical company is nearing completion.

The strategy focuses on five core therapeutic areas, major technology platforms, and the United States.

Over the past 12 months, NVS stock is down -6.84%. Novartis AG’s 1-year forecast is for a potential rally at 24.37. NVS stock currently has an average equity rating of 2.00, and is trading near a bullish pattern in the stock market.

The stock has a market capitalization of $185.83 billion, with 2.20 billion shares outstanding and 2.18 billion shares in current float. Compared to an average trading volume of 2.11 million shares, NVS stock reached a trading volume of 3,948,727 on the last trading day, which is why market watchers consider the stock to be active.

Guru’s opinion of Novartis AG [NVS]:

Based on careful, fact-backed analysis by Wall Street experts, the current consensus on a target price for NVS shares is $102.00 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus for NVS stock is a set recommendation at 2.00. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

Credit Suisse has made an estimate for Novartis AG stock, while maintaining their opinion of the stock as underperforming, with their previous recommendation back on September 15, 2022. The new note on price target was issued on September 14, 2022, which is the official price target for Novartis AG stock. .

The Average True Range (ATR) for Novartis AG is set at 1.27, with a price-to-sales ratio for NVS stock in the past twelve months at 3.52. The price-to-book ratio for the last quarter was 2.69, with the price-to-cash ratio for the stock in the same quarter set at 8.20. The price-to-free cash flow for NVS over the past 12 months was 34.53 with a Q4 quick ratio of 1.10.

NVS stock performance analysis:

Novartis AG [NVS] It fell into the red at the end of last week, fell in a negative direction and fell by -4.46. With this latest performance, NVS shares are down -7.59% over the past four-week period, and also -9.83% over the past six months – not to mention a -6.84% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for the NVS stock for the last two weeks was set at 27.63, with the RSI for the last one trading at 22.06, and the three-week RSI set at 31.86 for Novartis AG [NVS]. The current moving average for the last 50 trading days for this stock is 83.57 while it recorded at 79.13 for the last trading week, and 85.90 for the last 200 days.

An insight into the fundamentals of Novartis AG:

Operating margin for any stock indicates how profitable the investment is, and Novartis AG [NVS] The stock currently has an operating margin of +23.11 and a gross margin of +69.27. Novartis AG’s net margin is currently at +46.53.

The return on total capital for NVS is now 12.56, given recent momentum, and the company’s return on invested capital is 27.67. The return on equity for this stock rose to 39.33, with the return on assets remaining at 18.25. When it comes to the capital structure of this company, Novartis AG [NVS] It has a total debt to total equity ratio set at 45.86. Additionally, Total Debt to Total Capital NVS was recorded at 31.44, with Total Debt to Total Assets ending at 22.83. Long-term debt to equity of the company was recorded at 36.25, and long-term debt to total capital now at 24.85.

Reflecting on workforce efficiency at Novartis AG [NVS] It was able to generate an average of $210,515 per employee. Accounts receivable turnover is 5.88 with total asset turnover recorded at 0.39, and Novartis AG’s liquidity data is also interesting, with a quick ratio of 1.10 and a specific trading ratio of 1.40.


The company’s progress can be seen through the perspective of the EPS growth rate, while Wall Street analysts focus on forecasting the 5-year EPS growth rate for NVS. When it comes to the stated value, analysts expect Novartis AG’s 5-year EPS growth rate to rise to 4.14%.

Novartis AG [NVS] Insider position details

There are currently approximately $15,641 million, or 9.20% of NVS shares, in the hands of institutional investors. The three largest corporate owners of NVS shares are: DODGE & COX with ownership of 22,552,769, which represents approximately -19.004% of the company’s market capitalization and approximately 9.30% of the total institutional ownership; PRIMECAP MANAGEMENT CO / CA /, which owns 1,7604,080 shares with an approximate value of $1.36 billion in NVS stock; and LOOMIS SAYLES & CO LP, which currently holds $1.19 billion in NVS stock with ownership of approximately -10.527% of the company’s market capitalization.

Positions in Novartis AG shares increased by institutional investors at the end of July and at the time of the July report, as 434 institutional owners consolidated their positions in Novartis AG [NYSE:NVS] About 11,758,917 shares. In addition, the number of 530 investors decreased by 17,347,663 shares, while 255 investors held positions with 173,651,947 shares. The said changes put institutional holdings at 202,758,527 shares, according to the latest report from the Securities and Exchange Commission. NVS shares had 85 new institutional investors for a total of 1,699,949 shares, while 76 institutional investors sold deals totaling 1,112,564 shares during the same period.

Leave A Reply

Your email address will not be published.